KLCM Advisors Inc. Makes New $708,000 Investment in Cencora, Inc. $COR

KLCM Advisors Inc. acquired a new stake in shares of Cencora, Inc. (NYSE:COR) during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 2,265 shares of the company’s stock, valued at approximately $708,000.

Several other hedge funds and other institutional investors have also recently modified their holdings of COR. Mirae Asset Global Investments Co. Ltd. raised its holdings in shares of Cencora by 13.0% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 48,270 shares of the company’s stock valued at $15,086,000 after purchasing an additional 5,543 shares in the last quarter. AustralianSuper Pty Ltd purchased a new position in Cencora in the third quarter valued at $26,191,000. Mediolanum International Funds Ltd raised its stake in Cencora by 133.0% in the third quarter. Mediolanum International Funds Ltd now owns 56,293 shares of the company’s stock valued at $17,342,000 after buying an additional 32,138 shares in the last quarter. Advisors Asset Management Inc. raised its stake in Cencora by 40.3% in the third quarter. Advisors Asset Management Inc. now owns 17,302 shares of the company’s stock valued at $5,407,000 after buying an additional 4,973 shares in the last quarter. Finally, Rhumbline Advisers lifted its holdings in Cencora by 4.0% during the 3rd quarter. Rhumbline Advisers now owns 430,150 shares of the company’s stock worth $134,435,000 after buying an additional 16,539 shares during the last quarter. 97.52% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at Cencora

In other Cencora news, EVP Silvana Battaglia sold 1,677 shares of the stock in a transaction that occurred on Friday, December 19th. The stock was sold at an average price of $345.00, for a total transaction of $578,565.00. Following the completion of the sale, the executive vice president directly owned 18,796 shares of the company’s stock, valued at approximately $6,484,620. This trade represents a 8.19% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Elizabeth S. Campbell sold 3,351 shares of the business’s stock in a transaction that occurred on Friday, December 19th. The shares were sold at an average price of $342.10, for a total value of $1,146,377.10. Following the completion of the transaction, the executive vice president directly owned 23,891 shares in the company, valued at approximately $8,173,111.10. The trade was a 12.30% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 15,220 shares of company stock valued at $5,282,867 in the last ninety days. Insiders own 0.38% of the company’s stock.

Wall Street Analyst Weigh In

COR has been the topic of a number of recent analyst reports. Robert W. Baird set a $415.00 price objective on Cencora in a report on Tuesday, January 13th. Wells Fargo & Company boosted their target price on Cencora from $405.00 to $429.00 and gave the stock an “overweight” rating in a research note on Tuesday, February 10th. Barclays upped their price target on Cencora from $400.00 to $425.00 and gave the company an “overweight” rating in a report on Friday, February 13th. Wall Street Zen cut shares of Cencora from a “buy” rating to a “hold” rating in a report on Friday, November 28th. Finally, Jefferies Financial Group upgraded shares of Cencora from an “underperform” rating to a “buy” rating in a research report on Thursday, January 22nd. Eleven investment analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $399.00.

Cencora Stock Down 0.6%

COR stock opened at $350.15 on Thursday. The company has a market cap of $68.12 billion, a price-to-earnings ratio of 42.09, a price-to-earnings-growth ratio of 1.64 and a beta of 0.68. The company has a fifty day moving average price of $355.08 and a 200 day moving average price of $337.60. The company has a debt-to-equity ratio of 3.62, a current ratio of 0.92 and a quick ratio of 0.51. Cencora, Inc. has a 12 month low of $251.94 and a 12 month high of $377.54.

Cencora (NYSE:COR) last issued its quarterly earnings data on Wednesday, February 4th. The company reported $4.08 earnings per share (EPS) for the quarter, topping the consensus estimate of $4.04 by $0.04. Cencora had a net margin of 0.50% and a return on equity of 176.54%. The company had revenue of $85.93 billion for the quarter, compared to the consensus estimate of $86.12 billion. During the same period last year, the firm posted $3.73 EPS. Cencora’s revenue for the quarter was up 5.5% on a year-over-year basis. Sell-side analysts expect that Cencora, Inc. will post 15.37 earnings per share for the current year.

Cencora Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Monday, March 2nd. Investors of record on Friday, February 13th were given a $0.60 dividend. This represents a $2.40 annualized dividend and a yield of 0.7%. The ex-dividend date was Friday, February 13th. Cencora’s payout ratio is 28.85%.

Cencora Company Profile

Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.